Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Bank of America Corp DE increased its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,131,813 shares of the company’s stock after buying an additional 115,347 shares during the period. Bank of America Corp DE owned 0.51% of Sana Biotechnology worth $1,845,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Sana Biotechnology during the fourth quarter worth $239,000. Charles Schwab Investment Management Inc. boosted its holdings in Sana Biotechnology by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock worth $1,722,000 after buying an additional 8,666 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sana Biotechnology by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after buying an additional 26,601 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sana Biotechnology by 44.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock worth $2,538,000 after buying an additional 478,596 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Sana Biotechnology by 287.2% during the fourth quarter. Jane Street Group LLC now owns 367,855 shares of the company’s stock valued at $600,000 after purchasing an additional 272,862 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Trading Up 6.4%

NASDAQ:SANA opened at $2.34 on Wednesday. The company’s 50-day moving average price is $1.78 and its 200-day moving average price is $2.33. The company has a market cap of $527.62 million, a P/E ratio of -1.67 and a beta of 1.75. Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $7.91.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. On average, analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

SANA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sana Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.